» Articles » PMID: 37066100

Evolving a National Clinical Trials Learning Health System

Overview
Date 2023 Apr 17
PMID 37066100
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical trials generate key evidence to inform decision making, and also benefit participants directly. However, clinical trials frequently fail, often struggle to enroll participants, and are expensive. Part of the problem with trial conduct may be the disconnected nature of clinical trials, preventing rapid data sharing, generation of insights and targeted improvement interventions, and identification of knowledge gaps. In other areas of healthcare, a learning health system (LHS) has been proposed as a model to facilitate continuous learning and improvement. We propose that an LHS approach could greatly benefit clinical trials, allowing for continuous improvements to trial conduct and efficiency. A robust trial data sharing system, continuous analysis of trial enrollment and other success metrics, and development of targeted trial improvement interventions are potentially key components of a Trials LHS reflecting the learning cycle and allowing for continuous trial improvement. Through the development and use of a Trials LHS, clinical trials could be treated as a system, producing benefits to patients, advancing care, and decreasing costs for stakeholders.

Citing Articles

Embracing Generative Artificial Intelligence in Clinical Research and Beyond: Opportunities, Challenges, and Solutions.

Foote H, Hong C, Anwar M, Borentain M, Bugin K, Dreyer N JACC Adv. 2025; 4(3):101593.

PMID: 39923329 PMC: 11850149. DOI: 10.1016/j.jacadv.2025.101593.


Evaluating adoption and reach in a pragmatic randomized trial of community paramedicine for intermediate acuity patient care.

Ridgeway J, Sundt W, Krpata T, Glasgow A, Smith O, Lampman M J Clin Transl Sci. 2024; 8(1):e199.

PMID: 39655042 PMC: 11626601. DOI: 10.1017/cts.2024.646.


Evolving a national clinical trials learning health system.

Stensland K, Richesson R, Vince R, Skolarus T, Sales A Learn Health Syst. 2023; 7(2):e10327.

PMID: 37066100 PMC: 10091198. DOI: 10.1002/lrh2.10327.

References
1.
Bibbins-Domingo K, Helman A, Dzau V . The Imperative for Diversity and Inclusion in Clinical Trials and Health Research Participation. JAMA. 2022; 327(23):2283-2284. DOI: 10.1001/jama.2022.9083. View

2.
Soni P, Hartman H, Dess R, Abugharib A, Allen S, Feng F . Comparison of Population-Based Observational Studies With Randomized Trials in Oncology. J Clin Oncol. 2019; 37(14):1209-1216. PMC: 7186578. DOI: 10.1200/JCO.18.01074. View

3.
Woodward E, Matthieu M, Uchendu U, Rogal S, Kirchner J . The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci. 2019; 14(1):26. PMC: 6417278. DOI: 10.1186/s13012-019-0861-y. View

4.
Feyman Y, Provenzano F, David F . Disparities in Clinical Trial Access Across US Urban Areas. JAMA Netw Open. 2020; 3(2):e200172. PMC: 7049079. DOI: 10.1001/jamanetworkopen.2020.0172. View

5.
Meyer S, Woldu H, Sheets L . Sociodemographic diversity in cancer clinical trials: New findings on the effect of race and ethnicity. Contemp Clin Trials Commun. 2021; 21:100718. PMC: 7872971. DOI: 10.1016/j.conctc.2021.100718. View